 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || 4-iodo-[131I]-phenylalanine (TLX101) / Telix
Enrollment open, Trial initiation date: 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) (clinicaltrials.gov) - Apr 19, 2023
P1, N=12, Recruiting, Sponsor: Telix International Pty Ltd
Not yet recruiting --> Recruiting | Initiation date: Jul 2022 --> Apr 2023
- 4-iodo-[131I]-phenylalanine (TLX101) / Telix
IPAX-1: phase 1/2 study of 131 I-iodo-phenylalanine ( 131 I‑IPA) combined with external radiation therapy as treatment for patients with relapsed glioblastoma (Gardehalle I & II) - Sep 9, 2022 - Abstract #EANO2022EANO_520;
Urinalysis, vital signs, and ECG did not show any clinically relevant changes from baseline. There were no notable differences in safety and tolerability between groups.
- || 4-iodo-[131I]-phenylalanine (TLX101) / Telix
New P1 trial: 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) (clinicaltrials.gov) - Jul 11, 2022
P1, N=12, Not yet recruiting, Sponsor: Telix International Pty Ltd
- | 4-iodo-[131I]-phenylalanine (TLX101) / Telix
Trial completion date, Trial primary completion date: IPAX-1: 131I-IPA and Concurrent XRT in Recurrent GBM (clinicaltrials.gov) - Oct 6, 2021
P1/2, N=44, Active, not recruiting, Sponsor: Telix International Pty Ltd
There were no notable differences in safety and tolerability between groups. Trial completion date: Dec 2021 --> Oct 2022 | Trial primary completion date: Aug 2021 --> Jul 2022
- | 4-iodo-[131I]-phenylalanine (TLX101) / Telix
Enrollment closed: IPAX-1: 131I-IPA and Concurrent XRT in Recurrent GBM (clinicaltrials.gov) - Aug 20, 2021
P1/2, N=44, Active, not recruiting, Sponsor: Telix International Pty Ltd
Trial completion date: Dec 2021 --> Oct 2022 | Trial primary completion date: Aug 2021 --> Jul 2022 Recruiting --> Active, not recruiting
- | 4-iodo-[131I]-phenylalanine (TLX101) / Telix
Trial primary completion date: IPAX-1: 131I-IPA and Concurrent XRT in Recurrent GBM (clinicaltrials.gov) - Oct 19, 2020
P1/2, N=44, Recruiting, Sponsor: Telix International Pty Ltd
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2020 --> Aug 2021
- 4-iodo-[131I]-phenylalanine (TLX101) / Telix Pharma
[VIRTUAL] IPAX-1: Phase I/II study of 131I-iodo-phenylalanine combined with external radiation therapy as treatment for patients with glioblastoma multiforme. (Poster Board 69) - Feb 27, 2020 - Abstract #ASCO2020ASCO_237;
P1/2
131I-iodo-phenylalanine (131I-IPA) is a small-molecule amino acid derivative taken up by LAT-1 with designated orphan status in the United States and European Union for the treatment of GBM...IPAX-1 enrollments began in July 2019; the study will enroll up to 44 patients and is currently recruiting at five sites in Europe and Australia. Research Funding: Telix International Pty Ltd
- || 4-iodo-[131I]-phenylalanine (TLX101) / Telix
Enrollment open: IPAX-1: 131I-IPA and Concurrent XRT in Recurrent GBM (clinicaltrials.gov) - Apr 10, 2019
P1/2, N=44, Recruiting, Sponsor: Telix International Pty Ltd
Research Funding: Telix International Pty Ltd Not yet recruiting --> Recruiting
- || 4-iodo-[131I]-phenylalanine (TLX101) / Telix
New P1/2 trial: IPAX-1: 131I-IPA and Concurrent XRT in Recurrent GBM (clinicaltrials.gov) - Feb 21, 2019
P1/2, N=44, Not yet recruiting, Sponsor: Telix International Pty Ltd